blog-icon

Clinical research blog

Explore our blog for insights into the big questions in precision medicine and clinical research.

Podcast recap: Zornitza Stark on real-world impact from newborn genomic screening 

As genetic medicine has continued to advance, experts have consistently highlighted the importance of newborn genomic screening as a practical avenue for early ...
Continue reading

Understanding the gap between feasibility estimates and patient availability

Patient availability is often overestimated during trial planning. This usually starts at feasibility, where sites are asked to report how many patients they ha...
Continue reading

Podcast recap: Michelle Werner and Michael Severino on moving engineered tRNA and gene writing into the clinic

At the JPM Healthcare Conference 2026, the Genetics Podcast recorded a special episode from the Flagship Pioneering studio, bringing together two leaders advanc...
Continue reading

What strong site enablement really looks like: Lessons from Sano’s site expert

Trial sponsors often assume that site enablement is largely complete once a trial launches. Feasibility assessments, training materials, and startup timelines a...
Continue reading

Redefining accessibility in cell and gene therapies

Cell and gene therapy continues to advance across a growing number of rare genetic conditions. As more of these therapies move closer to the clinic, a central t...
Continue reading

The infrastructure gaps biopharma misses in rare and genetic trials

Rare and genetic programs increasingly depend on healthcare systems that are still adapting to the demands of precision medicine. Many of the constraints that a...
Continue reading

Podcast recap: Arabella Bouzigues on building a global research infrastructure for frontotemporal dementia

In a recent episode of The Genetics Podcast, host Patrick Short talked with Dr. Arabella Bouzigues, postdoctoral researcher and coordinator of the Genetic Front...
Continue reading

The forces shaping regulatory expectations in genomics-driven pharma

Regulatory expectations in genomics-driven drug development are evolving alongside scientific practice, clinical implementation, and policy. While formal guidan...
Continue reading

Podcast recap: Lisa Gurry on scaling early genetic diagnosis at GeneDx

In the latest episode of The Genetics Podcast, Patrick spoke with Lisa Gurry, Chief Business Officer at GeneDx. The conversation focuses on how GeneDx has built...
Continue reading

Lessons from recent FDA actions in precision medicine 

Over the past few years, several cell and gene therapies (CGTs) in precision medicine have received FDA Complete Response Letters (CRLs). As the agency increase...
Continue reading